Select Location
What is your delivery location?
We need your delivery location to continue browsing
Select Location
We need your delivery location to continue browsing
Prescription Required
zydus cadila
1 injection
Adalimumab
Keep in cold place
Delivering To:
Overview
Exemptia Injection (Adalimumab) is available in the form of an injection and a strength of 40mg/0.8 ml. This injection is used for the treatment of various conditions (rheumatoid arthritis, juvenile idiopathic arthritis, Crohn's disease, and ulcerative colitis). Adalimumab 40mg Injection works by blocking the action of chemical messengers, which are responsible for certain joint diseases. Before starting treatment, inform your physician if you have a history of heart, liver, and kidney disease. Do not self-administer Exemptia medication.
Rheumatoid arthritis
Rheumatoid arthritis
Polyarticular juvenile idiopathic arthritis
Enthesitis-related arthritis
Ankylosing spondylitis
Axial spondyloarthritis without radiographic evidence of ankylosing spondylitis
Psoriatic arthritis
Plaque psoriasis
Hidradenitis suppurativa
Crohn’s disease
Ulcerative colitis
Non-infectious uveitis
The following are the possible side effects that can occur during your treatment with Adalimumab 40mg injection. Contact your medical practitioner immediately if any of the above-mentioned side effects appear.
Nausea
Injection site reactions
Headache
Back pain
Vomiting
Numbness
Muscle pain
Irregular heartbeat
Bruising
Ear congestion
Black or tarry stools
Sleep disturbances
Upper respiratory tract infection
EXEMPTIA 40mg Injection should be administered by a qualified nurse or medical professional, and the recommended dosage is decided by your doctor according to your medical history and current health conditions. In case of an overdose of EXEMPTIA 40mg Injection, contact your medical practitioner immediately to avoid severe side effects.
Alcohol
unsafe
Do not consume alcohol while taking Adalimumab 40mg injection
Pregnancy
consult your doctor
Do not take Adalimumab 40mg injection without consulting the doctor, in case of pregnancy.
Breast Feeding
consult your doctor
Do not take Adalimumab 40mg injection if you're breastfeeding. Consultation of the doctor is advised.
Driving
danger
It is advisable not to drive or operate heavy machinery, you may feel dizzy as one of the side effects of Adalimumab 40mg injection.
Kidney
precaution
Do not take Adalimumab 40mg injection without a doctor's consultation in case of kidney problems.
Liver
precaution
Share your medical history with the doctor in case of liver disease before taking Adalimumab 40mg injection.
If you miss a dose of Adalimumab injection, contact your health professional as soon as possible. Try not to miss or skip your dosage of Exemptia injection.
Exemptia 40mg Injection is used for the treatment of various conditions (rheumatoid arthritis, juvenile idiopathic arthritis, Crohn's disease, ulcerative colitis).
Use Exemptia 40mg Injection as prescribed by your healthcare provider, and it should be administered under the supervision of a healthcare professional.
Some common side effects of Exemptia 40mg Injection are nausea, weakness, pale skin, irregular heartbeat, difficulty in breathing, vomiting, fever, etc.
It is advisable to consult your medical practitioner in case of an overdose of Exemptia 40mg Injection.
The use of Exemptia injection is not recommended in pregnancy.
Exemptia 40 mg. When administering injections to those who have liver or kidney disease, dosage modifications or caution may be necessary. Based on renal and hepatic function, medical professionals will determine the patient's condition and choose the right dosage.
At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.
Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.
Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.
We currently ship to:
Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!
Jani, R. H., Gupta, R., Bhatia, G., Rathi, G., Kumar, P. A., Sharma, R., Mendiratta, S. K. (2015). A prospective, randomized, double‑blind, multicentre, parallel‑group, active-controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC‑3197) and adalimumab (Humira) in patients with rheumatoid arthritis. International Journal of Rheumatic Diseases, 19(11), 1157–1168. https://doi.org/10.1111/1756-185X.12711.
Gharia, M., Kapoor, S., Kaushik, V. K., Jain, R., & Rao, V., et al. (2019). Real‑life Tolerability and effectiveness of adalimumab biosimilar in rheumatoid arthritis: ASPIRE registry data. Rheumatology and Therapy. https://doi.org/10.1007/s40744-019-0166-2
Kapoor, S., Kaushik, V. K., Jain, R., Rao, V. K. R., Gharia, M., et al. (2019). Real‑life tolerability and effectiveness of adalimumab biosimilar in ankylosing spondylitis: Adalimumab Biosimilar Patient Registry data. ACR Open Rheumatology, 1(8), 480–484. https://doi.org/10.1002/acr2.11067
Midha, Y., Kumar, N., Singhal, S., et al. (2023). Efficacy and safety of Exemptia™ (biosimilar adalimumab) in moderate-to-severe steroid-refractory ulcerative colitis: 24-week follow-up in a real-world setting. Biologics: Targets & Therapy (retrospective analysis). Patil, S. (2018). Low‑dose adalimumab biosimilar (ZRC‑3197) in the treatment of hidradenitis suppurativa. Indian Journal of Dermatology, Venereology and Leprology, 84(5), 745–747.
zydus cadila
Written By
Venika Choudhary
Medical Content Writer @ Magicine Pharma
I hold an M.Sc. in Microbiology and have a strong academic foundation in microbial sciences and applied biotechnology. I began my career with extensive hands-on research at CSIR laboratories, focusing on fungal enzyme production, studying fungal diversity in various ecosystems, and developing bio-pesticides as sustainable alternatives to chemical pesticides. This work deepened my understanding of fungal biology, bioactive compounds, and their pharmaceutical and agricultural applications. Transitioning from research, I now work as a medical content writer, where I combine my scientific expertise with a passion for clear and reliable healthcare communication. I apply my research background to create patient-friendly, compliant content for pharmaceutical companies and healthcare platforms, ensuring science is both trustworthy and accessible. Specializing in clear, accurate, and engaging content, I help patients make informed decisions and support pharmaceutical companies in delivering trusted information. Whether writing product descriptions, crafting disease awareness articles, or composing drug information leaflets, I consistently meet regulatory standards and address audience needs, making my content an asset for healthcare brands.
Reviewed By
Dr. Aditya Sarin - MBBS, MD, DrNB - Consultant Medical Oncology
Dr. Aditya Sarin, MBBS, MD, DrNB, is a highly qualified medical oncologist with profound research and clinical expertise, currently working at Sir Ganga Ram Hospital, New Delhi. He is also a member of the European Society of Medical Oncology (ESMO), a non-profit European organization dedicated to eradicating cancer by promoting comprehensive cancer care and advancing medical oncology. He has been honored with several awards, including the International Cancer Foundation scholarship (ESMO congress, 2022) and Young Medical Oncologist of the Year (Times of India, 2024). He is well-known for his breakthrough in oncology. Dr. Sarin is passionate about converting complex health information into a concise and clear form that is understandable to everyone, aiming to create awareness and cancer care among people.